Intrapleural streptokinase is effective and safe for children with multi-loculated empyema regardless of the time from disease onset

Acta Paediatrica
Joseph L MathewPankaj Vaidya

Abstract

This study compared the efficacy of administering intrapleural streptokinase to children with multi-loculated empyema within 14 days or at any time after disease onset. We studied children under 12 years with multi-loculated empyema who were admitted to a teaching hospital in Chandigarh, India, from July 2013 to June 2017. They received antibiotics, pleural drainage and intrapleural streptokinase. The first group received three doses within 14 days of disease onset, the second received three doses regardless of time after onset and the third group received four to six doses regardless of time after onset. The three phases lasted 18, 18 and 12 months, respectively. Of 195 children, 133 (68%) received streptokinase within 14 days, 46 (24%) beyond 14 days and 16 (8%) did not receive it. There was no difference in surgical decortication (14/133 versus 7/46, p > 0.05) and median hospitalisation duration (15 versus 14 days, p > 0.05) between administration before versus after 14 days. Median hospitalisation was shorter with four to six doses than three doses (11 versus 16 days, p < 0.01). Intrapleural streptokinase was effective for multi-loculated empyema even when it was administered more than 14 days after disease onset and four t...Continue Reading

References

Nov 13, 2003·Archives of Disease in Childhood·A K BaranwalL Kumar
Mar 27, 2004·American Journal of Respiratory and Critical Care Medicine·Andreas H DiaconChris T Bolliger
Feb 1, 2005·Thorax·I M Balfour-LynnUNKNOWN Paediatric Pleural Diseases Subcommittee of the BTS Standards of Care Committee
Jun 21, 2005·Pediatric Pulmonology·Adam Jaffé, Ian M Balfour-Lynn
Feb 24, 2006·Proceedings of the American Thoracic Society·Richard W Light
Sep 2, 2009·Journal of Paediatrics and Child Health·Roxanne StrachanUNKNOWN Australian Research Network in Empyema
May 12, 2010·Acta Paediatrica·Katarzyna KrenkeHania Szajewska
Dec 25, 2010·Journal of Indian Association of Pediatric Surgeons·Prema MenonY K Batra
May 10, 2011·Indian Journal of Pediatrics·Rashna DassDwijendra Mili
Sep 2, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John S BradleyUNKNOWN Pediatric Infectious Diseases Society and the Infectious Diseases Society of America
Mar 19, 2013·Indian Pediatrics·D NarayanappaAnil Kumar
Jun 27, 2013·Indian Pediatrics·Anil KumarAnju Garg
Jul 23, 2014·African Journal of Paediatric Surgery : AJPS·Vikas GoyalShashikant Dhir
Oct 29, 2014·Pediatrics·Claudia MarhuendaAntonio Moreno-Galdó
Aug 13, 2015·The Pediatric Infectious Disease Journal·Marco ZampoliHeather J Zar
Nov 4, 2015·Journal of Global Health·Joseph L MathewAnna Nilsson
Feb 24, 2017·Acta Médica Portuguesa·Ana CoelhoFátima Carvalho
Mar 10, 2017·The Journal of Thoracic and Cardiovascular Surgery·K Robert ShenBenjamin Kozower
Jun 3, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Susan C MorpethUNKNOWN PERCH Study Group

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.